China
Africa
Explore chapters and articles related to this topic
Precision or Personalized Medicine for Cancer Chemotherapy: Is There a Role for Herbal Medicine?
Published in Shaker A. Mousa, Raj Bawa, Gerald F. Audette, The Road from Nanomedicine to Precision Medicine, 2020
Zhijun Wang, Xuefeng Liu, Rebecca Lucinda Ka Yan Ho, Christopher Wai Kei Lam, Moses Sing Sum Chow
Since cancer chemotherapy often involves drug combination, a unified approach to optimize multidrug chemotherapy using a pharmacokinetic enhanced pharmacodynamic model has been developed. This model is based on the vascular endothelial growth factor receptor (VEGFR) signaling system characterized by ligand-receptor interactions, enzyme recruitment (Grb2-Sos, phospholipase Cγ (PLCγ), and phosphoinositide-3 kinase (PI3K)), and downstream mitogen-activated protein kinase and Akt cascade activation. Drugs targeting these mechanisms (a VEGF inhibitor, a PI3K inhibitor, a PLCγ inhibitor, and a mitogen-activated protein kinase inhibitor) and sunitinib can provide input to optimization-based control analyses. This method can capture the complexities of drug action, tailor cancer chemotherapy, and empower personalized medicine [56].
Precision or Personalized Medicine for Cancer Chemotherapy: Is There a Role for Herbal Medicine?
Published in Shaker A. Mousa, Raj Bawa, Gerald F. Audette, The Road from Nanomedicine to Precision Medicine, 2019
Zhijun Wang, Xuefeng Liu, Rebecca Lucinda Ka Yan Ho, Christopher Wai Kei Lam, Moses Sing Sum Chow
Since cancer chemotherapy often involves drug combination, a unified approach to optimize multidrug chemotherapy using a pharmacokinetic enhanced pharmacodynamic model has been developed. This model is based on the vascular endothelial growth factor receptor (VEGFR) signaling system characterized by ligand-receptor interactions, enzyme recruitment (Grb2-Sos, phospholipase Cγ (PLCγ), and phosphoinositide-3 kinase (PI3K)), and downstream mitogen-activated protein kinase and Akt cascade activation. Drugs targeting these mechanisms (a VEGF inhibitor, a PI3K inhibitor, a PLCγ inhibitor, and a mitogen-activated protein kinase inhibitor) and sunitinib can provide input to optimization-based control analyses. This method can capture the complexities of drug action, tailor cancer chemotherapy, and empower personalized medicine [56].
Analysis of long non-coding RNA profiled following MC-LR-induced hepatotoxicity using high-throughput sequencing
Published in Journal of Toxicology and Environmental Health, Part A, 2018
Cong Wen, Shu Yang, Shuilin Zheng, Xiangling Feng, Jihua Chen, Fei Yang
The phosphoinositide 3-kinase (PI3K)/AKT pathway is most frequently activated in human cancer progression involving cellular transformation, tumorigenesis and drug resistance (Mayer and Arteaga 2016). It is of interest that Miao et al. (2016) suggested that activation of PI3K/AKT by MC-LR induced matrix metalloproteinase-13 (MMP-13) overexpression resulting in the migration and invasion of colorectal cancer DLD-1 cells and HT-29 cells. Chen et al (2017, 2018) noted that MC-LR-mediated activation of PI3K/AKT pathway produced male reproductive dysfunction. In our study, target genes of differentially expressed lncRNA induced by MC-LR also activated the PI3K/AKT pathway, suggesting the observed liver damage may also be associated with PI3K/AKT pathway stimulation.
6-(2-Morpholinoethyl)-thiazolo[3,2-a]pyrimidin-5-one: A novel scaffold for the synthesis of potential PI3kα inhibitors
Published in Egyptian Journal of Basic and Applied Sciences, 2018
Ahmed R. Ali, Eman R. El-Bendary, Mariam A. Ghaly, Ihsan A. Shehata
The phosphoinositide 3-kinase (PI3K) pathway is an intracellular signaling pathway that has regulatory roles in cell survival, proliferation, and differentiation, and a critical role in tumorigenesis [8,9] . In cancer, multiple studies have investigated the therapeutic targeting of the PI3K pathway, and multiple inhibitors targeting PI3K and its isoforms, protein kinase B/AKT, and mammalian target of rapamycin (mTOR), have been developed [8]. A US patent reported thiazolopyrimidine compounds, substituted with a morpholine ring, of formulae I and II, with anticancer activity, and more specifically with PI3 kinase inhibitory activity. The compounds may inhibit tumor growth in mammals and may be useful for treating human cancer patients [10].